Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.

Ploessl, Cady; Pan, Alice; Maples, Kathryn T; Lowe, Denise K

Ploessl, Cady; Pan, Alice; Maples, Kathryn T; Lowe, Denise K.

Affiliation

Ploessl C; Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.
Pan A; Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.
Maples KT; Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.
Lowe DK; Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA denise.lowe@vcuhealth.org.

Ann Pharmacother ; 50(5): 416-22, 2016 May.

Article in En | MEDLINE | ID: mdl-26917818

Subject(s)

Antibodies, Monoclonal/therapeutic use; Neuroblastoma/drug therapy; Antibodies, Monoclonal/pharmacokinetics; Antibodies, Monoclonal/pharmacology; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Immunotherapy; Maintenance Chemotherapy; Neuroblastoma/immunology

Key words

cancer; formulary; immunology; monoclonal antibodies; pediatric hematology-oncology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal / Neuroblastoma Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Ann Pharmacother Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google